The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Precision medicine for metastatic breast cancer—limitations and solutions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9844 · Cited by 758
Jensen, E. V., & DeSombre, E. R. (1973) · Science · doi:10.1126/science.182.4108.126 · Cited by 752
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
MuSiC: Identifying mutational significance in cancer genomes
Dees, N. D., Zhang, Q., Kandoth, C., Wendl, M. C., Schierding, W., Koboldt, D. C., Mooney, T. B., Callaway, M. B., Dooling, D., Mardis, E. R., et al. (2012) · Genome Research · doi:10.1101/gr.134635.111 · Cited by 677
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. (2015) · Nature · doi:10.1038/nature13952 · Cited by 598
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
IntOGen-mutations identifies cancer drivers across tumor types
Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Tamborero, D., Schroeder, M. P., Jene-Sanz, A., Santos, A., & Lopez-Bigas, N. (2013) · Nature Methods · doi:10.1038/nmeth.2642 · Cited by 586
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Van Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Self-citationDe Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H. H., Ng, C. K. Y., Nuciforo, P., Bidard, F.-C., Aura, C., Saura, C., Peg, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu239 · Cited by 386
Baselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
Henderson, S., Chakravarthy, A., Su, X., Boshoff, C., & Fenton, T. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.012 · Cited by 345
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296
Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
Ignatiadis, M., Singhal, S. K., Desmedt, C., Haibe-Kains, B., Criscitiello, C., Andre, F., Loi, S., Piccart, M., Michiels, S., & Sotiriou, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5624 · Cited by 220
Self-citationSeliger, B., Ritz, U., Abele, R., Bock, M., Tampé, R., Sutter, G., Drexler, I., Huber, C., & Ferrone, S. (2001) · PubMed · Cited by 189
Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., Van den Abbeele, A. D., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 177
Soria, J.-C., DeBraud, F., Bahleda, R., Adamo, B., Andre, F., Dientsmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu390 · Cited by 173
Self-citationFunctional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170
Singh, V., Salunga, R. C., Huang, V. J., Tran, Y., Erlander, M. G., Plumlee, P., & Peterson, M. R. (2013) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2013.02.001 · Cited by 129
Atzori, F., Tabernero, J. M., Cervantes, A. M. R., Prudkin, L., Andreu, J., Rodríguez-Braun, E., Domingo, A., Guijarro, J., Cenzano, C. G., Rodon, J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3336 · Cited by 129
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Dolled-Filhart, M. P., Emancipator, K., Gonzalez, E. J., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s1-09 · Cited by 114
The AURORA initiative for metastatic breast cancer
Zardavas, D., Maetens, M., Irrthum, A., Goulioti, T., Engelen, K., Fumagalli, D., Salgado, R., Aftimos, P. G., Saini, K. S., Sotiriou, C. P., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.341 · Cited by 100
Schneeweiß, A., Chia, S., Hegg, R., Tausch, C., Deb, R., Ratnayake, J., McNally, V. A., Ross, G. A., Kiermaier, A. C., & Cortés, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3690 · Cited by 88
Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.-M., Abadie‐Lacourtoisie, S., Lévy, C., Legouffe, É., Lortholary, A. H., Pujade-Lauraine, É., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu497 · Cited by 88
Self-citationLoi, S., Michiels, S., Baselga, J. M., Bartlett, J. M. S., Singhal, S. K., Sabine, V. S., Sims, A. H., Sahmoud, T., Dixon, J. M., Piccart, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053292 · Cited by 85
Self-citationDrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies
Hua, X., Xu, H., Yang, Y., Zhu, J., Liu, P., & Lü, Y. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.07.003 · Cited by 80
Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also
Bartlett, J. M. S., McConkey, C. C., Munro, A. F., Desmedt, C., Dunn, J., Larsimont, D., O’Malley, F. P., Cameron, D., Earl, H. M., Poole, C. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.7869 · Cited by 64
Vacchelli, E., Galluzzi, L., Rousseau, V., Rigoni, A., Tesnière, A., Delahaye, N., Schlemmer, F., Menger, L., Sukkurwala, A. Q., Adjemian, S., et al. (2012) · OncoImmunology · doi:10.4161/onci.18684 · Cited by 55
Chen, X., Zhao, M., Hao, M., Sun, X., Wang, J., Mao, Y., Zu, L., Liu, J., Shen, Y., Wang, J., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0212 · Cited by 53
Suo, C., Hrydziuszko, O., Lee, D., Pramana, S., Saputra, D., Joshi, H. N., Calza, S., & Yudi Pawitan, Y. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv164 · Cited by 49
Besse, B., Soria, J., Yao, B., Kris, M. G., Chao, B. H., Cortot, A. B., Mazières, J., Socinski, M. A., Horn, L., Waqar, S. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.47 · Cited by 44
Arnedos, M., Drury, S., Afentakis, M., A’Hern, R., Hills, M., Salter, J., Smith, I. E., Reis-Filho, J. S., & Dowsett, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt575 · Cited by 44
Self-citationExpression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
André, F., Nahta, R., Conforti, R., Boulet, T., Aziz, M., Yuan, L. X. H., Meslin, F., Spielmann, M., Tomasic, G., Pusztai, L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm429 · Cited by 34
Self-citationCui, Y., Palii, S. S., Innes, C. L., & Paules, R. S. (2014) · Cell Cycle · doi:10.4161/15384101.2014.960729 · Cited by 31
Arnedos, M., Scott, V., Job, B., Cruz, J. D. L., Commo, F., Mathieu, M. C., Wolp-Diniz, R., Richon, C., Campone, M., Bachelot, T., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.014 · Cited by 29
Self-citationDickler, M. N., Bardia, A., Mayer, I. A., Winer, E. P., Rix, P. J., Hager, J., Chen, M., Chan, I. T., Chow‐Maneval, E., Arteaga, C. L., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct231 · Cited by 25
Hightower, M., Klem, J., Lee, D., Chu, E., Copur, S. M., & Jain, V. K. (2003) · Clinical Colorectal Cancer · doi:10.1016/s1533-0028(11)70462-5 · Cited by 24
Hyman, D. M., Blay, J., Chau, I., Raje, N. S., Élez, E., Wolf, J., Sirzén, F., Veronese, M. L., Mitchell, L., Puzanov, I. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2533 · Cited by 21
Jankú, F., Juric, D., Cortés, J., Rugo, H. S., Burris, H. A., Schüler, M., Deschler-Baier, B., Middleton, M. R., Gil-Martín, M., Berlin, J. D., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd5-5 · Cited by 17
Wagle, N., Lin, N., Richardson, A. L., Leshchiner, I., Mayer, I., Forero, A., Hobday, T. J., Dees, E. C., Nanda, R., Rimawi, M. F., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd3-5 · Cited by 6
Cited by
Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A., Stepanova, A., Iommarini, L., Mastroleo, C., Daly, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704862114 · Cited by 728
Genomic Evolution of Breast Cancer Metastasis and Relapse
Yates, L. R., Knappskog, S., Wedge, D., Farmery, J. H. R., Gonzalez, S., Martincorena, I., Alexandrov, L. B., Van Loo, P., Haugland, H. K., Lilleng, P. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.005 · Cited by 665
Organotropism: new insights into molecular mechanisms of breast cancer metastasis
Chen, W., Hoffmann, A. D., Liu, H., & Liu, X. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0047-0 · Cited by 385
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Metadata
- Authors
- Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-07-21
- Volume
- 12
- Issue
- 12
- Pages
- 693-704
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W964049080
- Cited by
- 317
- References
- 89
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.